Carmell Therapeutics Stock (NASDAQ:CTCX)

Revenue Financials Chart

Previous Close

$0.46

52W Range

$0.20 - $4.00

50D Avg

$0.35

200D Avg

$1.02

Market Cap

$13.83M

Avg Vol (3M)

$7.07M

Beta

0.31

Div Yield

-

CTCX Company Profile

Carmell Therapeutics Corporation focuses on the development of plasma-based bioactive material (PBM) to stimulate tissue repair or growth after injury, disease, and aging. Its lead product candidate is CT-101 bone healing accelerant for tibia fracture healing, foot/ankle fusion, spinal fusion, dental bone graft substitute, and bone void filler; and tissue healing accelerant for androgenetic alopecia and chronic wound healing. The company was founded in 2008 and is based in Pittsburgh, Pennsylvania.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

9

IPO Date

Sep 23, 2021

Website

CTCX Performance

CTCX Financial Summary

	Dec 23	Dec 22	Dec 21
Revenue	-	-	-
Operating Income	$-5.22M	$-5.51M	$-1.94M
Net Income	$-15.45M	$-9.05M	$-6.48M
EBITDA	$-5.09M	$-5.25M	$-1.66M
Basic EPS	$-1.40	$-0.46	$-0.33
Diluted EPS	$-1.40	$-0.46	$-0.33

Fiscal year ends in Dec 23 | Currency in USD